Search results
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Pharmaceutical Technology via Yahoo Finance· 7 days agoHowever, the exact mechanism of action is unknown, as per Neurocrine. Tardive dyskinesia is a rare...
No. 1 Biotech Stock Pops After Biggest Moneymaker Tops Sales Views
Investor's Business Daily· 7 days agoThe company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia.
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Investor's Business Daily· 7 days agoBut investors could also use the April 23 high of 145 as an early entry. Neurocrine Stock: Ingrezza...
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Investor's Business Daily· 4 days agoThe flat base forged next to a prior flat base. Aggressive investors could use Wednesday's high of...
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 6 days agoThe company recorded a significant charge of $89 million related to the settlement of convertible notes, impacting financials. While INGREZZA continues to grow, the market ...
Q1 2024 Neurocrine Biosciences Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoToday, May 1 marks the 7-year anniversary since the commercial launch of INGREZZA in 2017. After 7 years, INGREZZA is the #1 prescribed VMAT2 inhibitor ...
Neurocrine Biosciences shares jump 3% on earnings, revenue beat By Investing.com
Investing.com· 7 days agoNeurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) reported a notable increase in its...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 5 days agoAll of these will be key to helping bolster Neurocrine's sales. The company is well known for ...
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Reven
Guru Focus· 6 days agoTotal Revenue: Reported at $515.3 million for Q1 2024, up from $420.4 million in Q1 2023, surpassing estimates of $511.97 million.Net Income: Shifted to a GAAP
Neurocrine shares target lifted on neurocrine developments By Investing.com
Investing.com· 6 days agoThe primary endpoint of the study was the PANSS scale, where a 15-20 point difference from the...